{"id":565384,"date":"2026-09-20T12:30:00","date_gmt":"2026-09-20T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=565384"},"modified":"2026-09-20T17:47:53","modified_gmt":"2026-09-20T15:47:53","slug":"from-screening-to-multimodal-intervention-with-glp-1-ra-or-resmetirom","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/from-screening-to-multimodal-intervention-with-glp-1-ra-or-resmetirom\/","title":{"rendered":"From screening to multimodal intervention with GLP-1-RA or resmetirom"},"content":{"rendered":"\n

Metabolic dysfunction-associated steatotic liver disease (<\/em> MASLD) is one of the most common complications of obesity and diabetes. If fatty liver disease is not addressed through lifestyle changes and, if necessary, additional measures, it can progress to NASH. In its final stages, this can lead to cirrhosis, liver cancer, and even death. Studies indicate that GLP-1 agonists have the potential to improve fatty liver, steatohepatitis, and liver fibrosis. Another promising candidate is resmetirom. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Metabolic dysfunction-associated steatotic liver disease ( MASLD) is one of the most common complications of obesity and diabetes. If fatty liver disease is not addressed through lifestyle changes and, if……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":565386,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Obesity: More than half of those affected have fatty liver disease","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11548,11508,11384,11391,11297,11388,11503],"tags":[15144,65608,36018,17444],"powerkit_post_featured":[],"class_list":["post-565384","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-education","category-endocrinology-and-diabetology","category-gastroenterology-and-hepatology","category-general-internal-medicine","category-nutrition","category-studies","tag-fatty-liver","tag-glp-1-ra-en-2","tag-liver-fibrosis","tag-semaglutide-en-2","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-09-27 22:28:14","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":565388,"slug":"du-depistage-a-lintervention-multimodale-associant-un-agoniste-du-recepteur-du-glp-1-ou-le-resmetirom","post_title":"Du d\u00e9pistage \u00e0 l'intervention multimodale associant un agoniste du r\u00e9cepteur du GLP-1 ou le resmetirom","href":"https:\/\/medizinonline.com\/fr\/du-depistage-a-lintervention-multimodale-associant-un-agoniste-du-recepteur-du-glp-1-ou-le-resmetirom\/"},"it_IT":{"locale":"it_IT","id":565392,"slug":"dallo-screening-allintervento-multimodale-con-glp-1-ra-o-resmetirom","post_title":"Dallo screening all\u2019intervento multimodale con GLP-1-RA o resmetirom","href":"https:\/\/medizinonline.com\/it\/dallo-screening-allintervento-multimodale-con-glp-1-ra-o-resmetirom\/"},"pt_PT":{"locale":"pt_PT","id":565396,"slug":"desde-o-rastreio-ate-a-intervencao-multimodal-com-glp-1-ra-ou-resmetirom","post_title":"Desde o rastreio at\u00e9 \u00e0 interven\u00e7\u00e3o multimodal com GLP-1-RA ou resmetirom","href":"https:\/\/medizinonline.com\/pt-pt\/desde-o-rastreio-ate-a-intervencao-multimodal-com-glp-1-ra-ou-resmetirom\/"},"es_ES":{"locale":"es_ES","id":565404,"slug":"desde-el-cribado-hasta-la-intervencion-multimodal-con-glp-1-ra-o-resmetirom","post_title":"Desde el cribado hasta la intervenci\u00f3n multimodal con GLP-1-RA o resmetirom","href":"https:\/\/medizinonline.com\/es\/desde-el-cribado-hasta-la-intervencion-multimodal-con-glp-1-ra-o-resmetirom\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/565384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=565384"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/565384\/revisions"}],"predecessor-version":[{"id":565387,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/565384\/revisions\/565387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/565386"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=565384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=565384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=565384"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=565384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}